Table 4.
Clinical, genetic, pathologic, and biochemical features of the present cohort (n=136), stratified by whether or not triiodothyronine/thyroxine (T3/T4) ratio is <0.03
| Brain parenchymal T3/T4 ratio |
p-value: T3/T4 <0.03 vs >0.03 |
||
|---|---|---|---|
| >0.03 | <0.03 (lowest quintile) |
||
| n | 109 | 27 | N/A |
| Age at death, Avg | 83.6 | 85.3 | 0.487 |
| % Female | 58.7 | 51.9 | 0.519 |
| % Normal cognition/clinical state | 29.6 | 26.9 | 0.785 |
| % Demented cognition/clinical state | 56.5 | 57.7 | 0.911 |
| MMSE, Avg* | 21.0 | 18.1 | 0.189 |
| % SLCO1A2/IAPP risk allele(s) | 20.2 | 40.7 | 0.026 |
| % GRN risk allele(s) | 41.3 | 40.7 | 0.959 |
| % TMEM106B risk allele(s) | 81.7 | 88.9 | 0.567 |
| % ABCC9 risk allele(s) | 23.9 | 18.5 | 0.554 |
| % APOE ε4 allele [+1* | 31.6 | 28 | 0.73 |
| % Braak NFT stage V or VI* | 48.6 | 55.6 | 0.519 |
| % HS-Aging | 22.9 | 44.4 | 0.025 |
| DG: % [+] TDP-43 inclusions | 27 | 41 | 0.227 |
| DG: median # inclusions in [+] cases | 2 | 6 | |
| CA1: % [+] TDP-43 inclusions | 34 | 48 | 0.499 |
| CA1: median # inclusions in [+] cases | 5 | 13 | |
| CA1 TDP-43 neurites, median | 1.44E-03 | 1.52E-03 | 0.361 |
| Sub: % [+] TDP-43 inclusions | 27 | 41 | 0.569 |
| Sub: median # inclusions in [+] cases | 6 | 17 | |
| Sub TDP-43 neurites, median | 2.42E-03 | 1.15E-03 | 0.376 |
| % with Frontal Cx TDP-43 | 4.6 | 7.4 | 0.625 |
| T4 fg/mg brain tissue, Avg | 188.51 | 213.08 | N/A |
| T3 fg/mg brain tissue, Avg | 8.46 | 4.46 | N/A |
| Average of T3/T4 ratio, Avg | 0.044 | 0.021 | N/A |
| PMI (hrs), Avg | 4.8 | 4.7 | 0.648 |
*
-APOE genotype was available on 120/136 (88.2%) of the included subjects, and final MMSE scores were available for 126/136 (92.6%) of subjects.
N/A: Not applicable.